Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-08-09
2011-08-09
Kolker, Daniel E (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S388150
Reexamination Certificate
active
07993643
ABSTRACT:
Various human monoclonal antibodies that bind to human LOX-1 and inhibit the binding of in-vivo LOX-1 ligands to LOX-1, and the LOX-1-mediated incorporation of the ligands into cells, were obtained by immunizing human antibody-producing transgenic mice (created by genetic engineering) with soluble human oxidized LDL receptor (LOX-1). Furthermore, the human monoclonal antibodies were found to be effective in preventing and treating a variety of diseases.
REFERENCES:
patent: 5620687 (1997-04-01), Hart et al.
patent: 5945308 (1999-08-01), Tang et al.
patent: 5962260 (1999-10-01), Sawamura et al.
patent: 2001/0053539 (2001-12-01), Lauffer et al.
patent: 2045869 (1991-12-01), None
patent: 2315280 (1999-07-01), None
patent: 0464533 (1992-01-01), None
patent: 626390 (1994-11-01), None
patent: 0795605 (1997-09-01), None
patent: 9-121859 (1997-05-01), None
patent: 11-127855 (1999-05-01), None
patent: 11-239491 (1999-09-01), None
patent: 2000-109435 (2000-04-01), None
patent: WO 96/17058 (1996-06-01), None
patent: WO 99/32520 (1999-07-01), None
Janeway et al. Immunobiology: the immune system in health and disease, Third Ed., New York: Garland Pub, 1997, pp. 2:19-2:20.
Bianchi, Camillo, “Thrombocytopenia provoked by carrageenan in rabbits and the inhibitory effect of lysozyme”Agents and Actions(1982) 12(5): 657-661.
Campa, et al., “Polyinosinic acid induces TNF and NO production as well as NF-κB and AP-1 transcriptional activation in the monocyte-macrophage cell line RAW 264.7”Inflamm. Res. (2005) 54: 328-337.
Davidson, et al., “Haematological Changes Following Systemic Injection of Purified Carrageenans (Kappa, Lambda and Iota)”Br. J. exp. Path. (1981) 62: 529-539.
Fowler, et al, “Histological and Ultrastructural Changes Following Carrageenan Injection in the Mouse”J. Pathology(1980) 132: 63-79.
Gervasi, et al., “A New Low Molecular Weight Heparan Sulphate Antagonizes κ-Carrageenan-Induced Thrombosis in Rats”Pharmacological Research(1991) 24: 59-63.
Ishiguro, et al., “Syndecan-4 Deficiency Increases Susceptibility to κ-Carrageenan-Induced Renal Damage”Laboratory Investigation(2001) 81(4): 509-516.
Mehta, J.L. and D.Y. Li, “Identification and Autoregulation of Receptor for OX-LDL in Cultured Human Coronary Artery Endothelial Cells”Biochemical and Biophysical Research Communications(1998) 248: 511-514.
Popper, et al., “Reduction of carrageenan-bradykinin- and histamine-induced acute inflammation by experimental eosinophilia in rats”Immunology(1982) 46: 589-594.
Aoyama, et al., “Structure and chromosomal assignment of the human lectin-like oxidized low-density-lipoprotein receptor-1 (LOX-1) gene”Biochem J. 339(Pt. 1): 177-184 (1999).
Green, et al., “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs”Nat. Genet. 7(1):13-21 (1994).
Huang, et al., “Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages”Arterioscler Thromb. Vasc. Biol. 19(7):1600-1607 (1999).
Jakobovits, “Production of fully human antibodies by transgenic mice”Curr. Opin. Biotechnol. 6(5):561-566 (1995).
Janeway, et al.,Immunobiology: the immune system in health and disease, Third Ed., New York: Garland Pub. 1997.
Kakutani, et al., “A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1”Proc. Natl. Acad. Sci. USA 97(1):360-364 (2000).
Kataoka, et al., “Expression of Lectinlike Oxidized Low-Density Lipoprotein Receptor-1 in Human Atherosclerotic Lesions”Circulation99(24):3110-3117 (1999).
Li Dy, et al., “Upregulation of Endothelial Receptor for Oxidized Low-Density Lipoprotein (LOX-1) in Cultured Human Coronary Artery Endothelial Cells by Angiotensin II Type 1 Receptor Activation”Circ. Res. 84(9):1043-1049 (1999).
Lipsky, et al., “The carboxyl-terminal cytoplasmic domain of CD36 is required for oxidized low-density lipoprotein modulation of NF-kappaB activity by tumor necrosis factor-alpha”Recept. Signal Transduct. 7(1):1-11 (1997).
Morawietz, et al., “Angiotensin II Induces LOX-1, the Human Endothelial Receptor for Oxidized Low-Density Lipoprotein”Circulation100(9):899-902 (1999).
Morganelli, et al., “Evidence that human Fc gamma receptor IIA (CD32) subtypes are not receptors for oxidized LDL”Arterioscler. Thromb. Vasc. Biol. 17(11):3248-3254 (1997).
Moriwaki, et al., “Expression of lectin-like oxidized low density lipoprotein receptor-1 in human and murine macrophages: upregulated expression by TNF-α”FEBS Lett. 440(1-2):29-32 (1998).
Murase, et al., “Fluid Shear Stress Transcriptionally Induces Lectin-like Oxidized LDL Receptor-1 in Vascular Endothelial Cells”Circ. Res. 83(3):328-333 (1998).
Nagase, et al., “Enhanced Expression of Endothelial Oxidized Low-Density Lipoprotein Receptor (LOX-1) in Hypertensive Rats”Biochem Biophys Res. Commun. 237(3):496-498 (1997).
Nagase, et al., “Genomic Organization and Regulation of Expression of the Lectin-like Oxidized Low-density Lipoprotein Receptor (LOX-1) Gene”J. Biol. Chem. 273(50):33702-33707 (1998).
Nagase, et al., “Unique repetitive sequence and unexpected regulation of expression of rat endothelial receptor for oxidized low-density lipoprotein (LOX-1)”Biochem J., 330(Pt. 3):1417-1422 (1998).
Oka, et al., “Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic cells in endothelial cells”Proc. Natl. Acad. Sci. USA 95(16):9535-9540 (1998).
Sawamura, et al., “An endothelial receptor for oxidized low-density lipoprotein”,Nature, 386(6620):73-77 (1997).
Woo, et al., Homologous human macrophage hybridomas that produce a novel cytotoxic factor in their culture supernatantsMicrobiol. Immunol. 32(1):97-114 (1988).
Yamanaka, et al., “The Human Gene Encoding the Lectin-Type Oxidized LDL Receptor (OLR1) is a Novel Member of the Natural Killer Gene Complex with a Unique Expression Profile”Genomics54(2):191-199 (1998).
International Search Report, dated Jun. 12, 2007, issued in International Application No. PCT/JP01/01636.
Kamada Masafumi
Kobayashi Yuko
Sawamura Tatsuya
Tsuji Hiroyuki
Amgen Fremont Inc.
Emch Gregory S
Knobbe Martens Olson & Bear LLP
Kolker Daniel E
LandOfFree
Uses of human monoclonal antibodies against oxidized LDL... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Uses of human monoclonal antibodies against oxidized LDL..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of human monoclonal antibodies against oxidized LDL... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2736972